AzTrials
AzTrials

Atelectasis, PostoperativeNCT06210165

Effects of Sugammadex and Conventional Reversal on Lung Function in Laparoscopic Abdominal Surgery

A study testing Sugammadex and Neostigmine and atropine in people with Atelectasis, Postoperative and Pulmonary Function; Newborn, Abnormal, run by Rhendra Hardy Mohamad Zaini at 1 site in Malaysia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clincal trial is to determine the differences in few parameter of lung function (ie Forced Vital Capacity (FCV)) between Sugammadex and conventional reversal in laparoscopic abdominal surgery. The main questions it aims to answer are: 1. Read more about this study

Who is it for?
Ages 18 to 60 years
What is being tested?
Sugammadex and Neostigmine and atropine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteMalaysia
Study dates
7 Dec 2022to Jun 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Diagnosed / suspected: appendicitis or cholelithiasis
  • Planned for laparoscopic operation under general anaesthesia
  • ASA I-III

Who cannot join

  • Unstable haemodynamic status
  • Patient refusal to participate
  • Altered mental status, cognitive function or mental disorder
  • Admission to postoperative care unit (PACU) under mechanical ventilation
  • Hypersensitivity to any of the drugs
  • Acute or chronic lung diseases
Show all 12Show fewer
  • Neuromuscular disorders
  • Myocardial infarction or coronary occlusion three months prior surgery
  • Obesity BMI more or equal 30
  • Intubation prior operating room arrival
  • Pregnancy
  • Converted to open surgery

Trial locations and contacts

1 site in 1 country.

NIK MUHAMMAD 'AIZAT 'ADROS, MBBS contact

+60145333560

aizatadros@gmail.com

RHENDRA HARDY MOHAMAD ZAINI, MD contact

+6097673000 ext. 6095

rhendra@gmail.com

Malaysia1 site, 1 recruiting
  • University of Science Malaysia Hospital

    Kubang Kerian, Kelantan, 16150

    Rhendra Hardy Mohamad Zaini, MD, +6097673000 ext. 6095, rhendra@gmail.com

    Nik Muhammad 'Aizat 'Adros, MBBS

    Recruiting

Other trials in Malaysia

About this study

The goal of this clincal trial is to determine the differences in few parameter of lung function (ie Forced Vital Capacity (FCV)) between Sugammadex and conventional reversal in laparoscopic abdominal surgery. The main questions it aims to answer are:

  1. Is there differences in the pulmonary function test preoperative and post extubation between Sugammadex and conventional reversal in laparoscopic abdominal surgery?
  2. Is there differences in the size of atelectasis area between Sugammadex and conventional reversal in laparoscopic abdominal surgery?
  3. Is there differences between sugammadex and conventional reversal in postoperative mean length of stay in laparoscopic abdominal surgery?
Read more

Participants will be asked

  1. to do baseline spirometry before operation
  2. to be examined for lung ultrasound before operation
  3. to be given either sugammadex or neostigmine as reversal after operation is completed
  4. to repeat spirometry after operation for few times
  5. to be examined for lung ultrasound after operation

Researcher will compare sugammadex group and conventional group to see if any difference in term of lung function, size of atelectasis and length of stay.

Read the detailed description

Postoperative Pulmonary Complications (PPCs) are not uncommon. They increase healthcare resource usage as well as increase mortality of the patients. There are many definitions published in literature which can be considered as a composite outcome measure. This includes atelectasis, respiratory infection, respiratory failure, pleural effusion, pneumothorax, bronchospasm as well as aspiration pneumonitis (Jammer et al., 2015). After induction of general anaesthesia, the respiratory system changes occur immediately: muscle function and respiratory drive change, volume of lungs decreases, and atelectasis occurs in more than 75% of patients who were given neuromuscular blocking agent,

The problem and rationale of the study are described in the following paragraphs according to three postoperative conditions, 1) pulmonary function, 2) atelectasis, and 3) postoperative length of stay:

Postoperative pulmonary complications are one of the major problems after a surgery. Even if the surgery was successful, patient will still be facing morbidity or even mortality after the surgery. The risk of PPCs increases in patients having respiratory problem such as asthma, chronic obstructive pulmonary disease (COPD) and smoker . Many studies have shown the comparison between Sugammadex and conventionally used Neostigmine with respect to PPCs. However, studies regarding Sugammadex and Neostigmine in term of pulmonary function postoperative are still scarce as only two studies were found to comment directly on pulmonary function by using spirometry between neostigmine and sugammadex. In those studies, it shown that no significant different in term of spirometry volume postoperative between sugammadex and neostigmine . The authors believed postoperative analgesia plays important role in reported preservation of FVC.

Atelectasis as one of the commonest PPC can be worsen especially in laparoscopic surgery by the effect of Trendelenburg position and pneumoperitoneum. Residual paralysis even not in such condition (Trendelenburg, pneumoperitoneum) has been demonstrated to contribute to impaired upper airway and pulmonary function as well as respiratory adverse events in PACU and might make the atelectasis even worse. This shows that there is a need for an effective and complete reversal of neuromuscular blocker to prevent such event.

The length of stay after operation is important as it may present the quality of the health care system. However, there are many factors that can contribute to length of stay postoperative where postoperative pulmonary complications is one of the greatest contributors. A study which conducted by Ledowski et al. on elderly group more than 75 years old in centres across 5 countries (South Korea, Malaysia, Australia, Hungary, Netherlands) regarding comparison neostigmine and sugammadex showed that there is no significant different in length of stay. Only in Malaysia Ledowski et.al found that there is significant difference in terms of length of stay. Thus, further study is needed to compare the post operative length of stay between patients reversed with Sugammadex and Neostigmine.

From reviews of literatures, there is a gap in studies involving comparison of the effect of sugammadex and neostigmine as reversal. The gap lies in 1) the scarcity of studies involving Sugammadex and Neostigmine in terms of pulmonary function postoperative, 2) a need for an effective and complete reversal of neuromuscular blocker, and 3) further study on postoperative length of stay is needed.

Research Question(s)

  1. Are there differences in the pulmonary function test preoperative and post extubation between Sugammadex and conventional reversal in laparoscopic abdominal surgery?
  2. Are there differences in the size of atelectasis area between Sugammadex and conventional reversal in laparoscopic abdominal surgery?
  3. Are there differences between sugammadex and conventional reversal in postoperative mean length of stay in laparoscopic abdominal surgery?

Thus, we formulate from the research questions with null hypothesis as below:

  1. There is no difference in Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and FEV1/FVC preoperative and post extubation between Sugammadex and conventional reversal group in laparoscopic abdominal surgery
  2. There is no difference in the size of atelectasis area using ultrasonography preoperative and post extubation between sugammadex and conventional reversal in laparoscopic abdominal surgery
  3. There is no difference in mean postoperative length of stay (days) in hospital between sugammadex and conventional reversal in laparoscopic abdominal surgery Objective General: To compare the effect on lung function between sugammadex and conventional reversal in laparoscopic abdominal surgery

Specific:

  1. To compare the Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and FEV1/FVC using portable spirometry preoperative and post extubation between sugammadex and conventional reversal in laparoscopic abdominal surgery
  2. To identify and compare the size of atelectasis area using ultrasonography preoperative and post extubation between sugammadex and conventional reversal in laparoscopic abdominal surgery
  3. To compare mean postoperative length of stay (days) in hospital between sugammadex and conventional reversal in laparoscopic abdominal surgery

All data collection will be collected at Hospital Universiti Sains Malaysia, Kubang Kerian. Patient will be identified based on inclusion and exclusion criteria from locations listed below:

  1. Anaesthesia clinic
  2. In the ward, during review by preanaesthesia review for the elective operation in the following day
  3. In the ward, when cases are notified for operations as emergency case
  4. In operation theatre, when cases notified arrived for emergency operation.

The informed consent will be obtained from patients either in ward, clinics or in Operation Theatre during emergency premedication at the airlock. The patient will be given ample time to decide on the participation. The consent for general anaesthesia also will be taken as part of standard practice. Related information such as fasting hours will be conveyed.

After consent is explained and taken, baseline spirometry and lung ultrasound (LUS) will be performed before general anaesthesia given, either in wards, clinics or operation theatre. This to get the baseline of pulmonary function as well as lung images. Spirometry will be performed following international recommendations but with patients in a semi recumbent position (40 degree) as recommended for postoperative position (Graham et al., 2019). FVC, FEV1 and forced expiratory flow 25-75% will be measured and recorded. Changes in lung aeration will be studied by LUS with the patient in the same position. LUS will be conducted on each lung in sagittal section at three predefined areas: parasternal, medial axillary line, and posterior axillary line (Lichtenstein, 2014). Brightness will be adjusted in setting to the brightest level in the bony surface of ribs. After that, the scale in cm2 will be set according to image resolutions in pixels. Presence of hepatization pattern of lung tissue will indicate the collapsed area. This suggesting atelectasis is present. The area will be measured in each area by taking the longest length vertically and horizontally, during end-expiration after freezing the image. The sum of all six area will be added, recorded and considered as size of atelectasis.

Patient will be induced by anaesthesiologist in-charge as routine clinical practice. Neuromuscular block will be performed using rocuronium prior intubation and monitored by train-of-four (TOF) Watch. Anaesthesiologist will be allowed to maintain TOF level according to usual criteria. Desflurane or sevoflurane will be used as maintenance.

After operation is completed, patient will be randomly assigned to receive either sugammadex 4mg/kg or neostigmine 40mcg/kg in combination with atropine 10mcg/kg using sealed opaque envelopes. The reversal will be given once the TOF ratio ranging between 0.7 to 0.9 as the diaphragm muscles and tidal volume are already back to normal (Wardhana et al., 2019). An extra dose of reversal is permitted by protocol, when needed, at the discretion of the attending anaesthesiologist. Patient will be extubated as usual local practice and will be sent to postoperative recovery room.

In order to ensure patient able to obey command, new spirometry will be performed in the postoperative recovery room only after 20 minutes of extubation with the same procedure and position used in the preoperative determinations. Postoperative clinical management will be conducted according to clinical preferences and local protocol. Additional lung ultrasound scan is performed as well at 20 minutes post extubation, just after spirometry. The spirometry is repeated at 60 minutes post extubation. All measurements will be recorded.

Another spirometry will be done 24H after operation in ward in the same manner and measurement will be recorded. The patient will be followed up in ward until discharge and the length of stay postoperative will be recorded.

Being tested
Sugammadex, Neostigmine and atropine
Medical subject headings
Pulmonary Atelectasis, Antisocial Personality Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SugammadexDrug

    Also called Interventional Reversal

    IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery

  • Neostigmine and atropineDrug

    Also called Conventional reversal

    IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery

Study groups in NCT06210165
Study groupRoleWhat they receive
SugammadexExperimentalIV Sugammadex 4mg/kg once after Train of Four ratio 0.7 to 0.9
Receives: Drug: Sugammadex
Neostigmine and atropineActive comparatorIV Neostigmine 40mcg/kg and IV Atropine 10mcg/kg once after Train of Four ratio 0.7 to 0.9
Receives: Drug: Neostigmine and atropine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lung Function

    compare the Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and FEV1/FVC using portable spirometry preoperative and post extubation between sugammadex and conventional reversal in laparoscopic abdominal surgery

    Measured: Preoperative (Hour 1)to 24H post extubation (Hour 24)

Secondary outcomes (2)
  1. Atelectasis

    compare the size of atelectasis area using ultrasonography preoperative and post extubation between sugammadex and conventional reversal in laparoscopic abdominal surgery.

    Measured: Preoperative (baseline) and 20 minutes post extubation

  2. Length of stay

    compare mean postoperative length of stay (days) in hospital between sugammadex and conventional reversal in laparoscopic abdominal surgery

    Measured: Through study completion, an average one week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jan 2024
  2. Study start7 Dec 2022
  3. Primary completionJun 2024 (estimated)
  4. Study completionJun 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06210165
Sponsor's protocol ID
USM/JEPeM/22050289
Status last verified
Jan 2024
First submitted
27 Sep 2023
Last updated
18 Jan 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Abola RE, Romeiser J, Rizwan S, Lung B, Gupta R, Bennett-Guerrero E. A randomized-controlled trial of sugammadex versus neostigmine: impact on early postoperative strength. Can J Anaesth. 2020 Aug;67(8):959-969. doi: 10.1007/s12630-020-01695-4. Epub 2020 May 13.

    PubMed 32405975
  • Alday E, Munoz M, Planas A, Mata E, Alvarez C. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial. Can J Anaesth. 2019 Nov;66(11):1328-1337. doi: 10.1007/s12630-019-01419-3. Epub 2019 Jun 4.

    PubMed 31165457
  • Amorim P, Lagarto F, Gomes B, Esteves S, Bismarck J, Rodrigues N, Nogueira M. Neostigmine vs. sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quality Recovery Scale. Acta Anaesthesiol Scand. 2014 Oct;58(9):1101-10. doi: 10.1111/aas.12389. Epub 2014 Sep 1.

    PubMed 25179550
  • Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990 Apr;11(2):116-28. doi: 10.1016/0197-2456(90)90005-m.

    PubMed 2161310
  • Echeverry G, Polskin L, Tollinche LE, Seier K, Tan KS, McCormick PJ, Fischer GW, Grant FM. ROUTINE USE OF SUGAMMADEX DOES NOT SHORTEN PACU LENGTH OF STAY: A PROSPECTIVE DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. Perioper Care Oper Room Manag. 2021 Sep;24:100199. doi: 10.1016/j.pcorm.2021.100199. Epub 2021 Jul 16.

    PubMed 34504958
  • Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.

    PubMed 31613151
  • Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017 Aug 14;8(8):CD012763. doi: 10.1002/14651858.CD012763.

    PubMed 28806470
  • Hyman EC, Brull SJ. Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities. Anesthesiology. 2017 Oct;127(4):730. doi: 10.1097/ALN.0000000000001795. No abstract available.

    PubMed 28926458
  • Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, Leva B, Rhodes A, Hoeft A, Walder B, Chew MS, Pearse RM; European Society of Anaesthesiology (ESA) and the European Society of Intensive Care Medicine (ESICM); European Society of Anaesthesiology; European Society of Intensive Care Medicine. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015 Feb;32(2):88-105. doi: 10.1097/EJA.0000000000000118.

    PubMed 25058504
  • Kheterpal S, Vaughn MT, Dubovoy TZ, Shah NJ, Bash LD, Colquhoun DA, Shanks AM, Mathis MR, Soto RG, Bardia A, Bartels K, McCormick PJ, Schonberger RB, Saager L. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. Anesthesiology. 2020 Jun;132(6):1371-1381. doi: 10.1097/ALN.0000000000003256.

    PubMed 32282427
  • Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test. Restor Dent Endod. 2017 May;42(2):152-155. doi: 10.5395/rde.2017.42.2.152. Epub 2017 Mar 30. No abstract available.

    PubMed 28503482
  • Ledowski T, Szabo-Maak Z, Loh PS, Turlach BA, Yang HS, de Boer HD, Asztalos L, Shariffuddin II, Chan L, Fulesdi B. Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: a prospective, randomised, double-blind trial in high-risk older patients. Br J Anaesth. 2021 Aug;127(2):316-323. doi: 10.1016/j.bja.2021.04.026. Epub 2021 Jun 12.

    PubMed 34127252
  • Li L, Jiang Y, Zhang W. Sugammadex for Fast-Track Surgery in Children Undergoing Cardiac Surgery: A Randomized Controlled Study. J Cardiothorac Vasc Anesth. 2021 May;35(5):1388-1392. doi: 10.1053/j.jvca.2020.08.069. Epub 2020 Sep 3.

    PubMed 32962936
  • Lichtenstein DA. Lung ultrasound in the critically ill. Ann Intensive Care. 2014 Jan 9;4(1):1. doi: 10.1186/2110-5820-4-1.

    PubMed 24401163
  • Mazo V, Sabate S, Canet J. How to optimize and use predictive models for postoperative pulmonary complications. Minerva Anestesiol. 2016 Mar;82(3):332-42. Epub 2015 May 20.

    PubMed 25990430

Questions about this trial

What is this clinical trial studying?

A study testing Sugammadex and Neostigmine and atropine in people with Atelectasis, Postoperative and Pulmonary Function; Newborn, Abnormal, run by Rhendra Hardy Mohamad Zaini at 1 site in Malaysia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact NIK MUHAMMAD 'AIZAT 'ADROS, MBBS (+60145333560, aizatadros@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lung Function (time frame: Preoperative (Hour 1)to 24H post extubation (Hour 24)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06210165, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in